Reduction of Oxidative/Nitrosative stress in brain and its involvement in the neuroprotective effect of n-3 PUFA in Alzheimer’s disease

Current Alzheimer Research

Volumn 13, Issue 2, 2016, Pages 123-134

  Serini, Simona ^a   Calviello, Gabriella ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer s disease; Antioxidant; HO 1; Microglia; N 3 PUFA; Nrf2

Indexed keywords

HEME OXYGENASE 1; OMEGA 3 FATTY ACID; TRANSCRIPTION FACTOR NRF2; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; BRAIN; DRUG EFFECT; HUMAN; MACROPHAGE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; FATTY ACIDS, OMEGA-3; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 84959376156     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150921101147     Document Type: Article

References (148)

1. Han SH, Mook-Jung I. Diverse molecular targets for therapeutic strategies in Alzheimer’s disease. J Korean Med Sci 29: 893-902 (2014).
2. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer’s disease. Expert Rev Neurother 10: 711-28 (2010).
3. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59: 290-4 (2010).
4. Butterfield DA, Swomley AM, Sultana R. Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal 19: 823-35 (2013).
5. Mancuso C, Siciliano R, Barone E, Preziosi P. Natural substances and Alzheimer’s disease: from preclinical studies to evidence based medicine. Biochim Biophys Acta 1822: 616-24 (2012).
6. Calabrese V, Cornelius C, Mancuso C, Barone E, Calafato S, Bates T, et al. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. Front Biosci 14: 376-97 (2009).
7. Shelat PB, Chalimoniuk M, Wang JH, Strosznajder JB, Lee JC, Sun AY, et al. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106: 45-55 (2008).
8. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 362: 329-344 (2010).
9. Seripa D, Panza F, Franceschi M, D’Onofrio G, Solfrizzi V, Dallapiccola B, et al. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer’s disease. Ageing Res Rev 8: 214-36 (2009).
10. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 27: 5394-404 (2007).
11. Sultana R, Perluigi M, Butterfield DA. Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118: 131-150 (2009).
12. Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 62: 90-101 (2013).
13. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 377: 1019-31 (2011).
14. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 36: 747-51 (1994).
15. Nunomura A, Moreira PI, Castellani RJ, Lee HG, Zhu X, Smith MA, et al. Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox Res 22: 231-48 (2012).
16. Dildar K, Sinem F, Gokhan E, Orhan Y, Filiz M. Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia. Alzheimer Dis Assoc Disord 24: 194-7 (2010).
17. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Pratico D. Plasma F2A isoprostane levels in Alzheimer’s and Parkinson’s disease. Neurodegener Dis 4: 403-5 (2007).
18. Pratico D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12: 1777-83 (1998).
19. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 27: 262-9 (2006).
20. Sultana R, Piroddi M, Galli F, Butterfield DA. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33: 2540-6 (2008).
21. Calviello G, Serini S, Palozza P. n-3 polyunsaturated fatty acids as signal transduction modulators and therapeutical agents in cancer. Curr Signal Trans Ther 1: 255-71 (2006).
22. Calviello G, Serini S, Piccioni E. n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved. Curr Med Chem 14: 3059-69 (2007).
23. Calviello G, Serini S, Piccioni E, Pessina G. Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer 61: 287-301 (2009).
24. Calviello G, Su HM, Weylandt KH, Fasano E, Serini S, Cittadini A. Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res Int 2013: 743171 (2013).
25. Calviello G, Serini S, Piccioni E. Alzheimer s disease and n-3 polyunsaturated fatty acids: beneficial effects and possible molecular pathways involved. Curr Signal Trans Ther 3: 152-157 (2008).
26. Serini S, Bizzarro A, Piccioni E, Fasano E, Rossi C, Lauria A, et al. EPA and DHA differentially affect in vitro inflammatory cytokine release by peripheral blood mononuclear cells from Alzheimer’s patients. Curr Alzheimer Res 9: 913-23 (2012).
27. Calviello G, Resci F, Serini S, Piccioni E, Toesca A, Boninsegna A, et al. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 28: 1202-9 (2007).
28. Serini S, Fasano E, Piccioni E, Monego G, Cittadini AR, Celleno L, et al. DHA induces apoptosis and differentiation in human melanoma cells in vitro: involvement of HuR-mediated COX-2 mRNA stabilization and β-catenin nuclear translocation. Carcinogenesis 33: 164-73 (2012).
29. Fedorova I, Salem N Jr. Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot Essent Fatty Acids 75: 271-89 (2006).
30. Hajjaji N, Besson P, Bougnoux P. Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats. Cancer Chemother Pharmacol 70: 17-23 (2012).
31. Serini S, Fasano E, Piccioni E, Cittadini AR, Calviello G. Dietary n-3 polyunsaturated fatty acids and the paradox of their health benefits and potential harmful effects. Chem Res Toxicol 24: 2093-105 (2011).
32. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 126: 1-27 (2003).
33. Shaikh SR, Kinnun JJ, Leng X, Williams JA, Wassall SR. How polyunsaturated fatty acids modify molecular organization in membranes: Insight from NMR studies of model systems. Biochim Biophys Acta 1848: 211-219 (2015).
34. Erdogan H, Fadillioglu E, Ozgocmen S, et al. Effect of fish oil supplementation on plasma oxidant/antioxidant status in rats. Prostaglandins Leukot Essent Fatty Acids 71: 149-52 (2004).
35. Castillo RL, Arias C, Farias JG. Omega 3 chronic supplementation attenuates myocardial ischaemia-reperfusion injury through reinforcement of antioxidant defense system in rats. Cell Biochem Funct 32: 274-81 (2014).
36. Saw CL, Yang AY, Guo Y, Kong AN. Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway. Food Chem Toxicol 62: 869-75 (2013).
37. Avramovic N, Dragutinovic V, Krstic D, Colovic M, Trbovic A, de Luka S, et al. The effects of omega 3 fatty acid supplementation on brain tissue oxidative status in aged wistar rats. Hippokratia 16: 241-5 (2012).
38. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr 140: 869-74 (2010).
39. Farooqui AA. n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. Curr Med Chem 19: 532-43 (2012).
40. Hsieh HL, Yang CM. Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed Res Int 2013: 484613 (2013).
41. Laitinen M, Ngandu T, Rovio S, Helkala E, Uusitalo U, Viitanen M. Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement Geriatr Cogn Disord 22: 99-107 (2006).
42. Morris M, Evans D, Bienias J, Tangney C, Wilson R. Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology 62: 1573-9 (2004).
43. Solfrizzi V, Colacicco A, Introno A, Capurso C, Torres F, Rizzo C. Dietary intake of unsaturated fatty acids and age related cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. Neurobiol Aging 27: 1694-704 (2006).
44. Ubeda N, Achon M, Varela Moreiras G. Omega 3 fatty acids in the elderly. Br J Nutr 107: S137-S51 (2012).
45. Vercambre MN, Boutron-Ruault MC, Ritchie K, Clavel-Chapelon F, Berr C Long-term association of food and nutrient intakes with cognitive and functional decline: a 13-year follow-up study of elderly French women. Br J Nutr 102: 419-27 (2009).
46. Solfrizzi V, Colacicco A, D’Introno A, Capurso C, Del Parigi A, Capurso S. Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian longitudinal study on aging. Exp Gerontol 41: 619-27 (2006).
47. Barberger Gateau P, Peres K, Letenneur L, Deschamps V, Peres K, Dartigues J, et al. Fish, meat, and risk of dementia: cohort study. BMJ 325: 932-3 (2002).
48. Morris M, Evans D, Bienias J, Tangney C, Bennett D, Wilson R. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60: 940-6 (2003).
49. Huang T, Zandi P, Tucker K, Fitzpatrick A, Kuller L, Fried L. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon 4. Neurology 65: 1409-14 (2005).
50. Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues J. Dietary patterns and risk of dementia—the three-city cohort study. Neurology 69:1921-30 (2007).
51. Morris M, Evans D, Tangney C, Bienias J, Wilson R. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 62: 1849-53 (2005).
52. van Gelder B, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 85: 1142-7 (2007).
53. Eskelinen MH, Ngandu T, Helkala EL, Tuomilehto J, Nissinen A, Soininen H, et al. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry 23: 741-7 (2008).
54. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63: 1402-8 (2006).
55. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32: 1538-44 (2008).
56. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56: 159-64 (2006).
57. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304: 1903-11 (2010).
58. Lee LK, Shahar S, Chin AV, Yusoff NA. Docosahexaenoic acidconcentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology 225: 605-12 (2013).
59. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 6: 456-64 (2010).
60. Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 38: 111-20 (2014).
61. Irving GF, Freund-Levi Y, Eriksdotter-Jonhagen M, Basun H, Brismar K, Hjorth E, et al. Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease: the omega-3 Alzheimer’s disease study. J Am Geriatr Soc 57: 11-7 (2009).
62. Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxen-Irving G, Vedin I, et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study. Dement Geriatr Cogn Disord 27: 481-90 (2009).
63. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, et al. Inflammaging as a prodrome to Alzheimer’s disease. J Neuroinflamm 5: 51 (2008).
64. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 19: 355-61 (2010).
65. Neuroinflammation Working Group. Inflammation and Alzheimer’s disease. Neurobiol Aging 21: 383-421 (2000).
66. Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Maier W, Rao ML, et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer’s disease. Ann Neurol 45: 666-8 (1999).
67. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, et al. Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 47: 365-8 (2000).
68. Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C, et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer’s disease. Neurobiol Aging 25: 1009-15 (2004).
69. Nauroth JM, Liu YC, Van Elswyk M, Bell R, Hall EB, Chung G, et al. Docosahexaenoic acid (DHA) and docosapentaenoic acid(DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids 45: 375-84 (2010).
70. Lund T, Mangsbo SM, Scholz H, Gjorstrup P, Totterman TH, Korsgren O, et al. Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro. Exp Clin Endocrinol Diabetes 118: 237-44 (2010).
71. Ruggiero C, Lattanzio F, Lauretani F, Gasperini B, Andres-Lacueva C, et al. Omega-3 polyunsaturated fatty acids and immunemediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des 15: 4135-48 (2009).
72. Vedin I, Cederholm T, Freund Levi Y, Basun H, Garlind A, Faxen Irving G, et al. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr 87: 1616-22 (2008).
73. Pawlosky RJ, Hibbeln JR, Salem N Jr. Compartmental analyses of plasma n-3 essential fatty acids among male and female smokers and nonsmokers. J Lipid Res 48: 935-43 (2007).
74. Rees D, Miles EA, Banerjee T, Wells SJ, Roynette CE, Wahle KW, et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 83: 331-42 (2006).
75. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27: 4385-95 (2007).
76. Cole GM, Frautschy SA. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer’s disease mouse model. Nutr Health 18:249-59 (2006).
77. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5’-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 1182: 50-9 (2007).
78. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 43: 633-45 (2004).
79. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25: 3032-40 (2005).
80. He C, Qu X, Cui L, Wang J, Kang JX. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A 106: 11370-5 (2009).
81. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-43 (2000).
82. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356: 1627-31 (2000).
83. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-31 (2000).
84. Hashimoto M, Hossain S, Agdul H, Shido O. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta 1738: 91-8 (2005).
85. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 15: 159-66 (2005).
86. Gortan Cappellari G, Losurdo P, Mazzucco S, Panizon E, Jevnicar M, Macaluso L, et al. Treatment with n-3 polyunsaturated fatty acids reverses endothelial dysfunction and oxidative stress in experimental menopause. J Nutr Biochem 24: 371-9 (2013).
87. Kim YJ, Chung HY. Antioxidative and anti-inflammatory actions of docosahexaenoic acid and eicosapentaenoic acid in renal epithelial cells and macrophages. J Med Food 10: 225-31 (2007).
88. Abdou HM, Hassan MA. Protective role of omega-3 polyunsaturated fatty acid against lead acetate-induced toxicity in liver and kidney of female rats. Biomed Res Int 2014: 435857 (2014).
89. Jahangiri A, Leifert WR, Kind KL, McMurchie EJ. Dietary fish oil alters cardiomyocyte Ca2+ dynamics and antioxidant status. Free Radic Biol Med 40: 1592-602 (2006).
90. Okabe N, Nakamura T, Toyoshima T, Miyamoto O, Lu F, Itano T. Eicosapentaenoic acid prevents memory impairment after ischemia by inhibiting inflammatory response and oxidative damage. J Stroke Cerebrovasc Dis 20: 188-95 (2011).
91. Shimazawa M, Nakajima Y, Mashima Y, Hara H. Docosahexaenoic acid (DHA) has neuroprotective effects against oxidative stress in retinal ganglion cells. Brain Res 1251: 269-75 (2009).
92. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 7: 385-94 (2005).
93. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E, et al. A randomized controlled trial to prevent postoperative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 62: 1457-65 (2013).
94. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol 12: 525-35 (1997).
95. Preuss M, Girnun GD, Darby CJ, Khoo N, Spector AA, Robbins ME. Role of antioxidant enzyme expression in the selective cytotoxic response of glioma cells to gamma-linolenic acid supplementation. Free Radic Biol Med 28: 1143-56 (2000).
96. Ding WQ, Lind SE. Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid-induced cytotoxicity. Mol Cancer Ther 6: 1467-74 (2007).
97. Vibet S, Goupille C, Bougnoux P, Steghens JP, Gore J, Maheo K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44: 1483-91 (2008).
98. Ding WQ, Vaught JL, Yamauchi H, Lind SE. Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol Cancer Ther 3: 1109-17 (2004).
99. Hiratsuka S, Ishihara K, Kitagawa T, Wada S, Yokogoshi H. Effect of dietary docosahexaenoic acid connecting phospholipids on the lipid peroxidation of the brain in mice. J Nutr Sci Vitaminol 54: 501-6 (2008).
100. Ueda J. Lipoperoxides in diabetic retinopathy. Acta Soc Ophtalmol Jpn 73: 1367-78 (1969).
101. Hossain MS, Hashimoto M, Masumura S. Influence of docosahexaenoic acid on cerebral lipid peroxide level in aged rats with and without hypercholesterolemia. Neurosci Lett 244: 157-60 (1998).
102. Hossain MS, Hashimoto M, Gamoh S, Masumura S. Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. J Neurochem 72: 1133-8 (1999).
103. Dias IH, Polidori MC, Griffiths HR. Hypercholesterolaemiainduced oxidative stress at the blood-brain barrier. Biochem Soc Trans 42: 1001-5 (2014).
104. Kivipelto M, Helkala E, Laakso M, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322: 1447-51 (2001).
105. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer’s disease. Neuroepidemiology 17: 14-20 (1998).
106. Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol 69: 143-79 (2003).
107. Murray CA, Lynch MA. Dietary supplementation with vitamin E reverses the age-related deficit in long term potentiation in dentate gyrus. J Biol Chem 273: 12161-8 (1998).
108. Kelly L, Grehan B, Chiesa AD, O’Mara SM, Downer E, Sahyoun G, et al. The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat. Neurobiol Aging 32: 2318 e1-15 (2011).
109. O’Donnell E, Vereker E, Lynch MA. Age-related impairment in LTP is accompanied by enhanced activity of stress-activated protein kinases: analysis of underlying mechanisms. Eur J Neurosci 12: 345-52 (2000).
110. Vereker E, O’Donnell E, Lynch A, Kelly A, Nolan Y, Lynch MA. Evidence that interleukin-1beta and reactive oxygen species production play a pivotal role in stress-induced impairment of LTP in the rat dentate gyrus. Eur J Neurosci 14: 1809-19 (2001).
111. Wu FJ, Xue Y, Liu XF, Xue CH, Wang JF, Du L, et al. The protective effect of eicosapentaenoic acid-enriched phospholipids from sea cucumber Cucumaria frondosa on oxidative stress in PC12 cells and SAMP8 mice. Neurochem Int 64: 9-17 (2014).
112. Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev 45: 581-97 (2005).
113. Chaudhary M, Joshi DK, Tripathi S PhD, Kulshrestha S, Mahdi AA. Docosahexaenoic acid ameliorates aluminum induced biochemical and morphological alteration in rat cerebellum. Ann Neurosci 21: 5-9 (2014).
114. Deloncle R, Guillard O. Mechanism of Alzheimer’s disease: arguments for a neurotransmitter-aluminium complex implication. Neurochem Res 15: 1239-45 (1990).
115. Kawahara M, Muramoto K, Kobayashi K, Mori H, Kuroda Y. Aluminum promotes the aggregation of Alzheimer’s amyloid betaprotein in vitro. Biochem Biophys Res Commun 198: 531-5 (1994).
116. Savory J, Huang Y, Wills MR, Herman MM. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer’s disease. Neurotoxicology 19: 209-14 (1998).
117. Wu A, Ying Z, Gomez-Pinilla F. The salutary effects of DHA dietary supplementation on cognition, neuroplasticity, and membrane homeostasis after brain trauma. J Neurotrauma 28: 2113-22 (2011).
118. Zugno AI, Chipindo HL, Volpato AM, Budni J, Steckert AV, de Oliveira MB, et al. Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience 259: 223-31 (2014).
119. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebocontrolled trial. Arch Gen Psychiatry 67: 146-54 (2010).
120. Hashimoto M, Hossain S, Tanabe Y, Kawashima A, Harada T, Yano T, et al. The protective effect of dietary eicosapentaenoic acid against impairment of spatial cognition learning ability in rats infused with amyloid beta(1-40). J Nutr Biochem 20: 965-73 (2009).
121. Hammamieh R, Chakraborty N, Gautam A, Miller SA, Muhie S, Meyerhoff J, et al. Transcriptomic analysis of the effects of a fish oil enriched diet on murine brains. PLoS One 9: e90425 (2014).
122. Puertas MC, Martinez-Martos JM, Cobo MP, Carrera MP, Mayas MD, Ramirez-Exposito MJ. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp Gerontol 47: 625-30 (2012).
123. Cole GM, Ma QL, Frautschy SA. Omega-3 fattyacids and dementia. Prostaglandins Leukot Essent Fatty Acids 81: 213-21 (2009).
124. Barone E, Di Domenico F, Mancuso C, Butterfield DA. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it’s time for reconciliation. Neurobiol Dis 62: 144-59 (2014).
125. Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, et al. Biliverdin reductase--a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta 1812: 480-7 (2011).
126. Barone E, Di Domenico F, Cenini G, Sultana R, Coccia R, Preziosi P, et al. Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer’s disease and amnestic mild cognitive impairment. J Alzheimers Dis 25: 623-33 (2011).
127. Srisook K, Kim C, Cha YN. Molecular mechanisms involved in enhancing HO-1 expression: de-repression by heme and activation by Nrf2, the “one-two” punch. Antioxid Redox Signal 7: 1674-87 (2005).
128. Alam J, Cook JL. Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway. Curr Pharm Des 9: 2499-511 (2003).
129. Takahashi T, Morita K, Akagi R, Sassa S. Heme oxygenase-1: a novel therapeutic target in oxidative tissue injuries. Curr Med Chem 11: 1545-61 (2004).
130. Zhang M, Wang S, Mao L, Leak RK, Shi Y, Zhang W, et al. Omega-3 fatty acids protect the brain against ischemic injury by activating Nrf2 and upregulating heme oxygenase 1. J Neurosci 34: 1903-15 (2014).
131. Long EK, Picklo MJ Sr. Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: make some room HNE. Free Radic Biol Med 49: 1-8 (2010).
132. Kang JX. Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids 77: 263-7 (2007).
133. Liu Q, Wu D, Ni N, Ren H, Luo C, He C, et al. Omega-3 polyunsaturated fatty acids protect neural progenitor cells against oxidative injury. Mar Drugs 12: 2341-56 (2014).
134. Lu DY, Tsao YY, Leung YM, Su KP. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for ω-3 fatty acids. Neuropsychopharmacology 35: 2238-48 (2010).
135. Wang H, Khor TO, Saw CL, Lin W, Wu T, Huang Y, et al. Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol Pharm 7: 2185-93 (2010).
136. Yang YC, Lii CK, Wei YL, Li CC, Lu CY, Liu KL, et al. Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF-κB pathways. J Nutr Biochem 24: 204-12 (2013).
137. Chang CY, Kuan YH, Li JR, Chen WY, Ou YC, Pan HC, et al. Docosahexaenoic acid reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. J Nutr Biochem 24: 2127-37 (2013).
138. Gursoy-Ozdemir Y, Can A, Dalkara T. Reperfusion-induced oxidative/ nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 35: 1449-53 (2004).
139. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40: 1849-57 (2009).
140. Kawashima A, Harada T, Imada K, Yano T, Mizuguchi K. Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferatoractivated receptor-gamma. Prostaglandins Leukot Essent Fatty Acids 79: 59-65 (2008).
141. Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis 35: 697-713 (2013).
142. Pettit LK, Varsanyi C, Tadros J, Vassiliou E. Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin. Lipids Health Dis 12: 16 (2013).
143. Ajmone-Cat MA, Salvatori ML, De Simone R, Mancini M, Biagioni S, Bernardo A, et al. Docosahexaenoic acid modulates inflammatory and antineurogenic functions of activated microglial cells. J Neurosci Res 90: 575-87 (2012).
144. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hon JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 452-62 (2007).
145. DeLegge MH, Smoke A. Neurodegeneration and inflammation. Nutr Clin Pract 23: 35-41 (2008).
146. Kumar A, Chen SH, Kadiiska MB, Hong JS, Zielonka J, Kalyanaraman B, et al. Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced protein radical formation in murine microglial BV2 cells. Free Radic Biol Med 73: 51-9 (2014).
147. McGeer PL, McGeer EG. Targeting microglia for the treatment of Alzheimer’s disease. Expert Opin Ther Targets 29: 1-10 (2014).
148. Milton RH, Abeti R, Averaimo S, DeBiasi S, Vitellaro L, Jiang L, et al. CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia. J Neurosci 28: 11488-99 (2008).